This is an old revision of this page, as edited by Farmacol (talk | contribs) at 07:16, 6 May 2012. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 07:16, 6 May 2012 by Farmacol (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.003.692  |
| Chemical and physical data | |
| Formula | C5H7N3O4 |
| Molar mass | 173.127 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Azaserine is a carcinogen primarily used for researching pancreatic cancer in animal models. It is a glutamine analogue that irreversibly inhibits glutamine utilizing enzymes such as Gln: Phosphoribosyl Amidotransferase, which is involved in the biosynthesis of Inosine monophosphate (IMP). IMP is an important precursor to the purine nucleotides which include Adenosine monophosphate (AMP) and Guanosine monophosphate (GMP).
Further enzymes of purine and pyrimidine metabolism are inhibited as well. Therefore it was tested as anti-cancer drug by different authors in different indications (not only pancreatic cancer) in pre-clinical settings. Further glutamine analogues that were tested as anti-cancer drugs are DON and Acivicin.
References
Rao MS. 1987 Animal models of exocrine pancreatic carcinogenesis. Cancer Metastasis Rev. 1987;6(4):665-76.
Christophe J. 1994 Pancreatic tumoral cell line AR42J: an amphicrine model. Am J Physiol. 1994 Jun;266(6 Pt 1):G963-71.
Longnecker DS and Wilson GL "Ch.32, Pancreas " pp 227-254, Handbook of Toxicologic Pathology (eds Haschek WM etal. 2nd Edition) 2 Vols., Publ. Elsevier, New York, London.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |